Ocrelizumab and COVID-19 Pharmacovigilance Data

Main takeaways

- While it is too early to draw definitive conclusions, based on the limited information that is available from pharmacovigilance data, the risk factors for severe COVID-19 outcomes do not indicate a difference between ocrelizumab-treated patients[1] and the general population[2–10], and may suggest that COVID-19 follows a similar course in ocrelizumab-treated MS patients as in the general population[1–10]
  - These risk factors for severe COVID-19 include old age and presence of comorbidities such as hypertension, diabetes, obesity, smoking, cardiovascular and lung disease[1–4,8,9]
- The known benefit/risk profile of ocrelizumab remains unchanged

Incidence of COVID-19 cases in ocrelizumab-treated patients[1]

- As of 31 May 2020, 201 cases of COVID-19 in ocrelizumab-treated patients were identified in pharmacovigilance reports; all cases were conservatively considered as having confirmed COVID-19 (including the cases with missing information on diagnosis confirmation, e.g. by PCR)
- More than 160,000 people with MS have been treated with ocrelizumab globally, in clinical trial and real-world settings; data continue to show a consistent and favourable benefit/risk profile
- Patients receiving ocrelizumab that are either exposed to SARS-CoV-2 or confirmed to have COVID-19, should contact their neurologist or other medical professional right away, and patients should consult their neurologist or other medical professional before discontinuing their medication

Seriousness and outcomes of COVID-19 in ocrelizumab-treated patients[1]

- Of the 201 cases, 61% (n=122/201) were reported as not serious, and 39% (n=79/201) were reported as serious
  - Included in the serious cases were:
    - 2.0% (n=4/201) reported as life-threatening and 5.5% (n=11/201) reported a fatal outcome
    - 65% (n=51/79) of cases were classified as serious on the basis of hospitalisation
    - Reasons for hospitalisation were variable and included (but were not limited to) the following: treatment of pneumonia and for ICU treatment
    - At the time of reporting, 32% (n=25/79) of the serious cases were reported as recovered/recovering, and 33% (n=26/79) cases had an unknown outcome

Table 1: Reported outcomes by most serious seriousness criterion[a] for all serious cases (n=79)[1]

		Reported Outcome					
		Fatal	Recovered	Recovering	Not recovered	Missing information	Total
Most serious seriousness criterion	**All serious cases**	**11**	**15**	**10**	**17**	**26**	**79**
	Medically significant	0	3	2	2	5	12
	Hospitalisation	0	11	8	14	18	51
	Disability	0	0	0	0	1	1
	Life-threatening	0	1	0	1	2	4
	Death	11	0	0	0	0	11

Details of 11 cases with a fatal outcome[1]

- For the 11 cases with fatal outcomes the reported causes of death were: COVID-19 (n=8); COVID-19 pneumonia (n=1); coronavirus infection (n=1); and respiratory failure (n=1)
  - None of the 11 cases had an available autopsy report
- Patient demographics for these cases were as follows: Sex: male (n=7), female (n=3), unspecified (n=1); Age range 43–66 years (n=10), unspecified (n=1)
- The majority (n=7) of the 11 cases with fatal outcomes had risk factors known to be associated with severe COVID-19 outcomes in the general population
  - Reported previous DMTs (n=2); of note, as indicative of a more advanced MS
  - Reported EDSS 6.0–9.0 (n=5), indicating a more severe course; MS registries identified MS severity as risk factor for severe COVID-19 outcomes
  - Risk factors were identified for all patients with COVID-19 confirmed by RT-PCR (n=4), and all patients who received mechanical ventilation (n=5)
  - Two patients were not assessable; follow-up for missing information is ongoing
- Time from starting ocrelizumab to outcome ranged from 1.5 to 3 years, but was unknown in 2 cases

Date of preparation: July 2020

Interpreting COVID-19 real-world data

- COVID-19 is caused by a new strain of coronavirus called SARS-CoV-2, so knowledge about how it may affect people with MS remains limited[11,12]
  - The limited data that are emerging on COVID-19 in people with MS are mainly derived from real world data sources and it is important to recognise the limitations (and biases) inherent in these data sources[13,14]
- From the limited real world evidence available globally, the MS population in general does not seem to be at higher risk from COVID-19 and no association between any DMTs and fatal COVID-19 outcomes has been reported
  - Major risk factors identified for severe/fatal COVID-19 in the MS population are advanced age (>50 years old), high levels of disability, progressive form of MS and presence of comorbidities such as hypertension, diabetes, obesity, smoking, cardiovascular, and lung disease[9,15,16]
  - Treatment decisions, should therefore be made between a patient and their treating neurologist or other medical professional based on a benefit/risk assessment specific to the individual patient
- We are aware of many efforts to collect real world evidence to inform the community's understanding of COVID-19 and the impact on patients with MS including the CoviSEP (French) and MuSC-19 (Italian) registries[4,9,15]
- Real-world evidence is complex and challenging to interpret as there are many limitations and biases in the data sets including significant unknown and/or unreported data, differences in data collection and reporting (patient reported vs healthcare professional reported), suspected vs confirmed COVID-19 cases, identification of other co-morbidities and generally a reporting bias towards more severe cases

Table 2: Number of cases and deaths in the general population, as of 14 July 2020[16]

Country	France	Italy	USA	Global
Confirmed COVID-19 cases, n[b]	209,640	243,230	3,363,056	13,127,030
COVID-19 deaths, n[b]	30,032	34,967	135,605	573,663
Case–fatality rate , %	14.3	14.4	4.0	4.4

Table 3: Number of cases and deaths in MS datasets, including reported ocrelizumab cases

MS datasets	CoViSEP France[9] (as of 21 May 2020)	MuSC-19 Italy[17] (as of 31 May 2020)	CoViMS North America[18] (as of 14 July 2020)	MSDA/MSIF Global[c,16,19] (as of 10 June 2020)
COVID-19 cases (OCR cases), n[b]	347 (38)	789 (83)	362 (110)	457[d] (85)
COVID-19 deaths (OCR cases), n	12 (0)	13 (1)	24 (4)	18 (3)
Case–fatality rate (OCR cases), %	3.5 (0.0)	1.6 (1.2)	6.6 (3.6)	3.9 (3.5)

NB: numbers and percentages in brackets indicate ocrelizumab cases

- Due to limitations of real-world data and countries being affected differently by the pandemic, there may be differences in emerging data and interpretations
  - Publication in peer-reviewed journals of the real world evidence will provide a robust assessment of the data quality and analytical methods, especially accounting for potential confounders and biases, which is essential to understand the impact of COVID-19 in MS

Prescribing Information

Indications vary in different countries. The local prescribing information from your country is the primary source of information on the known and potential risks associated with ocrelizumab.

Footnotes: a, serious event is defined as one that requires in-patient hospitalisation, prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, is life-threatening or fatal; b, includes both clinically suspected and laboratory confirmed cases; c, Includes data from Germany, Sweden, Denmark, Brazil, North America; d, Overall dataset includes 527 cases, with alive/death status available for 457 patients

Abbreviations: COVID-19, coronavirus disease 2019; DMTs, disease-modifying therapies; EDSS, Expanded Disability Status Scale; ICU, intensive care unit; MS, multiple sclerosis; PPMS, primary progressive MS; RMS, relapsing forms of MS; RT-PCR, reverse transcription polymerase chain reaction; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2

References: 1. Roche data on file; 2. Hughes R et al. Mult Scler Relat Disord 2020;42:102192; 3. Richadson S et al. JAMA., 2020;323:2052–2059; 4. Sormani MP et al. Lancet Neurology. 2020 ;19:481-482; 5. Montero-Escribano P et al., Mult Scler Relat Disord 2020;42:102185; 6. Safavi F et al.. Mult Scler Relat Disord 2020;43:102195; 7. Barzegar M et al. Mult Scler Relat Disord 2020;45:102276; 8. Sormani MP et al. SSRN. Preprint – not yet peer reviewed. 363124413; 9. Louapre C et al. JAMA Neurol 2020;e20258114; 10. Dalla Costa G et al. Neurol Sci 2020;41:1647-1650; 11. Zhou P et al. Nature 2020;579:270-273; 12. del Rio C, and Preeti NM, JAMA. 2020;doi: 10.1001/jama.2020.3072; 13. Cohen JA et al. Mult Scler. 2020;26:23-37; 14. Evans K. Drugs Real World Outcomes 2019;6:43-45; 15. MS International Federation. COVID-19 & MS data sharing: for healthcare professionals. www.msif.org/covid-19-ms-data-sharing-for-healthcare-professionals Accessed 14 July 2020; 16. Johns Hopkins, Coronavirus Resource Center. Mortality analyses. https://coronavirus.jhu.edu/data/mortality Accessed 14 July 2020; 17. Unpublished MuSC-19 Italian Registry data, as of 31 May 2020; 18. CoViMS North American Registry data, as of 14 July 2020; 19. Unpublished MSDA/MSIF Global Sharing Initiative Data, as of 10 June 2020.

Date of preparation: July 2020